Front Page VSPN Message Boards Chat Library Continual Education Search MyVSPN - Coming Soon Help Frequently Asked Questions Send us Feedback! Go to VIN Industry Partners Go to VetQuest Go to Veterinary Partner Go to Y2Spay
 
Menu bar   Go to the VIN.com Portal
 

ABSTRACT OF THE WEEK

Journal of internal medicine

Vagus nerve stimulation: a new promising therapeutic tool in inflammatory bowel disease.

J Intern Med. July 2017;282(1):46-63.
B Bonaz1, V Sinniger2, S Pellissier3
1 University Clinic of Hepato-Gastroenterology, University Hospital, Grenoble, France.; 2 University Clinic of Hepato-Gastroenterology, University Hospital, Grenoble, France.; 3 University Clinic of Hepato-Gastroenterology, University Hospital, Grenoble, France.
© 2017 The Association for the Publication of the Journal of Internal Medicine.

Abstract

Inflammatory bowel disease (IBD), that is Crohn's disease (CD) and ulcerative colitis, affects about 1.5 million persons in the USA and 2.2 million in Europe. The pathophysiology of IBD involves immunological, genetic and environmental factors. The treatment is medico-surgical but suspensive. Anti-TNFα agents have revolutionized the treatment of IBD but have side effects. In addition, a non-negligible percentage of patients with IBD stop or take episodically their treatment. Consequently, a nondrug therapy targeting TNFα through a physiological pathway, devoid of major side effects and with a good cost-effectiveness ratio, would be of interest. The vagus nerve has dual anti-inflammatory properties through its afferent (i.e. hypothalamic-pituitary-adrenal axis) and efferent (i.e. the anti-TNFα effect of the cholinergic anti-inflammatory pathway) fibres. We have shown that there is an inverse relationship between vagal tone and plasma TNFα level in patients with CD, and have reported, for the first time, that chronic vagus nerve stimulation has anti-inflammatory properties in a rat model of colitis and in a pilot study performed in seven patients with moderate CD. Two of these patients failed to improve after 3 months of vagus nerve stimulation but five were in deep remission (clinical, biological and endoscopic) at 6 months of follow-up and vagal tone was restored. No major side effects were observed. Thus, vagus nerve stimulation provides a new therapeutic option in the treatment of CD.

Article Tools:
   Medline
   Email to me

Databanks:
GENBANK/NCT01569503
GENBANK/NCT02311660

Archives Highlights:
Challenges and Outlook of Veterinary Education in Iran: A Survey of Veterinary Students at Urmia University During the COVID-19 Pandemic.
Regarding future employment, 45.8% of participants wanted to start their own business or practice, whereas 54.2% preferred employment opportunities. A significant 81.6% of participants said they would consider emigrating to pursue better career prospects.
Splenic Masses in Dogs: Algorithms for Differentials, Diagnosis, and Definitive Treatment
There is a 63.1% to 70.5% chance a splenic mass is benign if there is no hemoabdomen and a 21.7% to 37.5% chance it is benign if there is hemoabdomen. These numbers replace the two-thirds rule, which said that two-thirds of splenic masses were malignant and two-thirds of malignant masses were HSA, without accounting for hemoabdomen.
Effective treatment with afoxolaner (NexGard) of Trixacarus caviae in a pet guinea pig.
The animal was treated with a single oral dose of 2.50 mg/kg afoxolaner, and the lesions, presence/absence of mites, and intensity of pruritus were evaluated periodically until 2 months post-treatment. A week after the medication, the lesions were milder, but pruritus was still present and was attributed to the healing process. Further examinations showed significant improvement with the complete remission of clinical signs and no mites at the microscopic examination after 4 weeks.
Elimination Diet Trials: Steps for Success and Common Mistakes
Increasing the duration of the EDT to 8 weeks increases the sensitivity to more than 90% for the diagnosis of food allergies in dogs and cats. The time to flare upon oral challenge with the offending diet can be 7 to 14 days.
Life tables of annual life expectancy and risk factors for mortality in cats in the UK.
Life expectancy at age 0 for UK companion cats overall was 11.74 years. Among the 12 breeds (including crossbred) analysed, Burmese and Birman had the longest life expectancy at year 0, showing 14.42 years and 14.39 years, respectively. Sphynx had the shortest life expectancy at year 0 among the analysed breeds at 6.68 years. Being entire, purebred, and with a non-ideal body weight were significantly linked to a decreased lifespan.

Back Print Save Bookmark in my Browser Email this article to me. Top of Page. VSPN AOW : Vagus nerve stimulation: ...
Contact Us